Hypofractionated radiation therapy for prostate cancer: biologic and technical considerations

Area of Science:

• Radiation Oncology
• Medical Physics

Background:

• The optimal radiation schedule for curative prostate cancer treatment remains unknown.
• The alpha-beta ratio (α/β) describes tissue response to fractionated irradiation, with evidence suggesting a low α/β for prostate cancer (1-3).
• A low α/β ratio supports the hypothesis that hypofractionation (less frequent, larger radiation doses) may improve treatment efficacy.

Purpose of the Study:

• To evaluate the efficacy and toxicity of hypofractionated radiation therapy compared to standard fractionation for prostate cancer.
• To explore the potential benefits of hypofractionation, including cost savings and improved patient outcomes.

Main Methods:

• Multiple randomized trials comparing moderate hypofractionation ( < 5 Gy/day) with standard radiation therapy.
• Ongoing randomized trial comparing extreme hypofractionation (≥ 5 Gy/day).
• Analysis of prospectively collected data from multiple institutions for extreme hypofractionation.

Main Results:

• Moderate hypofractionation demonstrated equivalent efficacy with similar or improved side effect profiles in most studies.
• Caution is advised for patients with baseline urinary dysfunction (IPSS > 12) due to increased urinary toxicity in one study.
• Early data on extreme hypofractionation shows favorable efficacy and toxicity compared to historical controls.

Conclusions:

• Hypofractionation appears to be a potentially more efficacious and cost-effective radiation schedule for prostate cancer.
• Further long-term data and trials are necessary to establish the ideal fractionation scheme based on cost, efficacy, and toxicity.
• Careful patient selection may be needed to mitigate potential increases in urinary toxicity with hypofractionation.